|国家科技期刊平台
首页|期刊导航|中国医院用药评价与分析|度洛西汀在抑郁症患者中血药浓度/剂量比的影响因素研究

度洛西汀在抑郁症患者中血药浓度/剂量比的影响因素研究OACSTPCD

Influencing Factors of Duloxetine on Blood Concentration/Dose Ratio in Patients with Depression

中文摘要英文摘要

目的:探讨抑郁症患者口服度洛西汀后血药浓度/剂量比(C/D)的影响因素,为临床实施个体化用药提供参考.方法:回顾性收集 2020-2022 年我院服用度洛西汀的住院患者血药浓度监测数据样本 264 份,分析性别、年龄、民族、体重指数(BMI)、合并疾病、联合用药、药品厂家和吸烟对度洛西汀C/D值的影响.结果:度洛西汀平均日剂量为(54.55±13.10)mg/d,平均稳态血药浓度为(69.14±22.87)ng/mL,平均C/D值为(1.44±0.62)ng·d/(mL·mg).女性患者的度洛西汀C/D值明显高于男性(P<0.05);回族患者的度洛西汀C/D值明显高于哈萨克族(P<0.01);正常组(BMI为 18.5~<24.0)和超重组(BMI为 24.0~<28.0)患者的度洛西汀C/D值高于肥胖组(BMI≥28.0)(P<0.05);联合奥氮平和联合曲唑酮患者的度洛西汀C/D值高于联合喹硫平患者(P<0.05);合并高血压患者的度洛西汀C/D值高于无合并疾病患者(P<0.05),上述差异均有统计学意义.药品厂家与度洛西汀C/D值无相关性(P>0.05);年龄、吸烟与度洛西汀C/D值的相关性仍需进一步扩大样本量验证.结论:度洛西汀具有较大的个体间药动学差异,性别、民族、BMI、合并疾病及联合用药均可引起度洛西汀的血药浓度波动.因此,临床医师或药师应结合患者血药浓度和临床疗效,及时调整、优化个体给药方案.

OBJECTIVE:To probe into the influencing factors of blood concentration/dose ratio(C/D)after oral administration of duloxetine in patients with depression,so as to provide reference for clinical implementation of individualized medication.METHODS:A total of 264 samples of blood concentration monitoring data of inpatients receiving duloxetine in our hospital from 2020 to 2022 were retrospectively collected,the effects of gender,age,nationality,body mass index(BMI),complicating disease,drug combination,drug manufacturer and smoking on C/D value of duloxetine were analyzed.RESULTS:The mean daily dose of duloxetine was(54.55±13.10)mg/d,the mean steady-state blood concentration was(69.14±22.87)ng/mL,and the mean C/D value was(1.44±0.62)ng·d/(mL·mg).The C/D value of duloxetine in female patients was significantly higher than that in male patients(P<0.05);the C/D value of duloxetine in patients of Hui nationality was significantly higher than those of Kazak nationality(P<0.01);the C/D value of duloxetine in normal group(BMI from 18.5 to<24.0)and overweight group(BMI from 24.0 to<28.0)were higher than that in obese group(BMI≥28.0)(P<0.05);the C/D value of duloxetine in patients received drug combination of olanzapine and trazodone were higher than that of quetiapine(P<0.05);the C/D value of duloxetine in patients complicated with hypertension was higher than that with no complicating disease(P<0.05),the differences were statistically significant.There was no correlation between drug manufacturers and the C/D value of duloxetine(P>0.05),the correlation between age and smoking and the C/D value of duloxetine still needed to be verified by further expanding sample size.CONCLUSIONS:Duloxetine has large inter-individual pharmacokinetic differences,the gender,nationality,BMI,complicating disease and drug combination can cause fluctuations in blood concentration of duloxetine,therefore,clinicians or pharmacists should adjust and optimize the individual dosing regimen in combination with patient's blood concentration and clinical efficacy in time.

谯明;朱毅;靳路;杨建华

新疆医科大学第一附属医院药学部,乌鲁木齐 830011||新疆药物临床研究重点实验室,乌鲁木齐 830011新疆医科大学第一附属医院心理医学中心,乌鲁木齐 830011

药学

度洛西汀血药浓度/剂量比影响因素抑郁症

DuloxetineBlood concentration/dose ratioInfluencing factorsDepression

《中国医院用药评价与分析》 2024 (006)

672-675,680 / 5

新疆维吾尔自治区自然科学基金资助项目(No.2022D01C749)

10.14009/j.issn.1672-2124.2024.06.007

评论